The expression of some of these receptors has been reported to be affected by pathological conditions, with LYVE-1 (along with stabilin-1, stabilin-2, and FcγRIIb) being downregulated in human liver cancer (HCC) and cirrhosis (Mouta Carreira et al., 2001; Geraud et al., 2013), and LSECtin being downregulated in HCC (Aizarani et al., 2019). This evidence concerns the gene STAB2 and hepatocellular carcinoma.